Yes, combining Januvia (sitagliptin) with Jardiance (empagliflozin) is safe and effective for type 2 diabetes.
The combination of Januvia and Jardiance is explicitly supported by FDA labeling, clinical guidelines, and robust research evidence showing no drug-drug interactions and complementary mechanisms of action. 1, 2
Evidence Supporting This Combination
FDA Drug Label Confirmation
The FDA label for Jardiance specifically states that empagliflozin pharmacokinetics were similar with and without coadministration of sitagliptin in healthy volunteers, indicating no clinically significant drug interaction 2. Additionally, empagliflozin had no clinically relevant effect on sitagliptin pharmacokinetics 2.
Guideline Support for Combination Therapy
The 2025 BMJ guideline explicitly states that "most medications for which recommendations are provided can be used in combination" and specifically notes that SGLT-2 inhibitors (like Jardiance) and DPP-4 inhibitors (like Januvia) have different mechanisms of action and can be combined 3. The guideline emphasizes that recent evidence supports additive effects when combining these drug classes 3.
The 2024 American College of Physicians guideline recommends adding SGLT-2 inhibitors to metformin for cardiovascular and kidney benefits, though it recommends against adding DPP-4 inhibitors specifically for mortality reduction 4. However, this doesn't prohibit their combination—it simply prioritizes SGLT-2 inhibitors as the preferred add-on agent.
Clinical Evidence
Pharmacokinetic Studies
A dedicated drug-drug interaction study demonstrated that coadministration of empagliflozin 50 mg with sitagliptin 100 mg showed no clinically relevant effects on the pharmacokinetics of either drug 5. The geometric mean ratios for both drugs remained within acceptable ranges, and the combination was well tolerated with no drug-related adverse events during coadministration 5.
Long-Term Safety and Efficacy
Multiple studies confirm the safety and effectiveness of this combination:
A 24-month study of triple therapy (metformin + sitagliptin + empagliflozin) in drug-naïve patients showed excellent glycemic control with 61.7% achieving HbA1c <7% at 24 months, with no serious adverse events including ketoacidosis 6
A 78-week extension study demonstrated sustained glycemic control and good tolerability when empagliflozin and sitagliptin were used together 7
A 2026 meta-analysis comparing empagliflozin versus sitagliptin as add-ons to metformin showed both were well tolerated, with empagliflozin offering superior glycemic and cardiometabolic benefits 8
Practical Considerations
When to use this combination:
- Patient already on Januvia with inadequate glycemic control who would benefit from cardiovascular/kidney protection
- Patient already on Jardiance needing additional glycemic control without weight gain concerns
- Patient requiring triple therapy with metformin as the base
Key monitoring points:
- Genital infections are more common with Jardiance (3-5.5% incidence) 7
- Urinary tract infections occur with both drugs (3.8-12.7% with empagliflozin, 12.5% with sitagliptin) 7
- Hypoglycemia risk remains low with this combination 6, 7
- Monitor kidney function as Jardiance efficacy depends on adequate renal function 2
Avoid this combination if:
- The patient has type 1 diabetes or diabetic ketoacidosis 1
- Severe renal impairment is present (limits Jardiance effectiveness)
- History of recurrent genital infections (relative contraindication for Jardiance)
- The additive cost burden outweighs anticipated benefits
Bottom Line
This is an FDA-approved, guideline-supported combination with proven safety and no drug-drug interactions. The combination provides complementary mechanisms: Jardiance reduces glucose reabsorption in kidneys while providing cardiovascular/kidney protection, and Januvia enhances incretin activity to improve insulin secretion. Both drugs can be taken together without dose adjustments 5.